One year in review 2017: novelties in the treatment of rheumatoid arthritis

被引：6
作者：
Ferro, F. [1 ]
Elefante, E. [1 ]
Luciano, N. [1 ]
Talarico, R. [1 ]
Todoerti, M. [2 ]
机构：
[1] Univ Pisa, Dept Clin & Expt Med, Rheumatol Unit, Via Roma 67, I-56126 Pisa, Italy
[2] Univ Pavia, Dept Rheumatol, IRCCS S Matteo, Pavia, Italy
来源：
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY | 2017年 / 35卷 / 05期
关键词：
rheumatoid arthritis; therapy; DMARDs; TNF-inhibitor; small molecules; new treatment; MODIFYING ANTIRHEUMATIC DRUGS; NECROSIS-FACTOR INHIBITORS; B-VIRUS REACTIVATION; LOW DISEASE-ACTIVITY; OPEN-LABEL; INADEQUATE RESPONSE; BACKGROUND METHOTREXATE; EULAR RECOMMENDATIONS; RECEIVING RITUXIMAB; CERTOLIZUMAB PEGOL;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Rheumatoid arthritis (RA) is a chronic disease characterised by inflammation of the synovial tissue in joints, which can lead to joint destruction. The primary goal of the treatment is to control pain and inflammation, reduce joint damage and disability, and maintain or improve physical function and quality of life. The present review is aimed at providing a critical analysis of the recent literature on the novelties in the treatment of RA, with a particular focus on the most relevant studies published over the last year.
引用
收藏
页码：721 / 734
页数：14
相关论文
共 101 条
  • [11] 2-E
  • [12] Outcomes of tumor necrosis factor inhibitor cycling versus switching to a disease-modifying anti-rheumatic drug with a new mechanism of action among patients with rheumatoid arthritis
    Chastek, Benjamin
    Becker, Laura K.
    Chen, Chieh-I
    Mahajan, Puneet
    Curtis, Jeffrey R.
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2017, 20 (05) : 464 - 473
  • [13] Efficacy of glucocorticoids, conventional and targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of The EULAR recommendations for the management of rheumatoid arthritis
    Chatzidionysiou, Katerina
    Emamikia, Sharzad
    Nam, Jackie
    Ramiro, Sofia
    Smolen, Josef
    van der Heijde, Desiree
    Dougados, Maxime
    Bijlsma, Johannes
    Burmester, Gerd
    Scholte, Marieke
    van Vollenhoven, Ronald
    Landewe, Robert
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 (06) : 1102 - 1107
  • [14] Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaboration
    Chatzidionysiou, Katerina
    Lie, Elisabeth
    Nasonov, Evgeny
    Lukina, Galina
    Hetland, Merete Lund
    Tarp, Ulrik
    Ancuta, Ioan
    Pavelka, Karel
    Nordstrom, Dan C.
    Gabay, Cem
    Canhao, Helene
    Tomsic, Matija
    van Riel, Piet L. C. M.
    Gomez-Reino, Juan
    Kvien, Tore K.
    van Vollenhoven, Ronald F.
    [J]. ARTHRITIS RESEARCH & THERAPY, 2016, 18
  • [15] Hepatitis B Virus Reactivation in Rheumatoid Arthritis Patients Undergoing Biologics Treatment
    Chen, Ming-Han
    Chen, Ming-Huang
    Liu, Chun-Yu
    Tsai, Chang-Youh
    Huang, De-Feng
    Lin, Hsiao-Yi
    Lee, Mei-Hsuan
    Huang, Yi-Hsiang
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2017, 215 (04) : 566 - 573
  • [16] A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy
    Choe, Jung-Yoon
    Prodanovic, Nenad
    Niebrzydowski, Jaroslaw
    Staykov, Ivan
    Dokoupilova, Eva
    Baranauskaite, Asta
    Yatsyshyn, Roman
    Mekic, Mevludin
    Porawska, Wieskawa
    Ciferska, Hana
    Jedrychowicz-Rosiak, Krystyna
    Zielinska, Agnieszka
    Choi, Jasmine
    Rho, Young Hee
    Smolen, Josef S.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 (01) : 58 - 64
  • [17] Biologic therapies and infections in the daily practice of three Italian rheumatologic units: a prospective, observational study
    Cipriani, Paola
    Berardicurti, Onorina
    Masedu, Francesco
    D'Onofrio, Francesca
    Navarini, Luca
    Ruscitti, Piero
    Maruotti, Nicola
    Margiotta, Domenico Paolo Emanuele
    Liakouli, Vasiliki
    Di Benedetto, Paola
    Carubbi, Francesco
    Valenti, Marco
    Cantatore, Francesco Paolo
    Afeltra, Antonella
    Giacomelli, Roberto
    [J]. CLINICAL RHEUMATOLOGY, 2017, 36 (02) : 251 - 260
  • [18] Pregnancy Outcomes in the Tofacitinib Safety Databases for Rheumatoid Arthritis and Psoriasis
    Clowse, Megan E. B.
    Feldman, Steven R.
    Isaacs, John D.
    Kimball, Alexandra B.
    Strand, Vibeke
    Warren, Richard B.
    Xibille, Daniel
    Chen, Yan
    Frazier, Donald
    Geier, Jamie
    Proulx, James
    Marren, Amy
    [J]. DRUG SAFETY, 2016, 39 (08) : 755 - 762
  • [19] Anti-therapeutic antibodies and their clinical impact in patients treated with the TNF antagonist adalimumab
    Cludts, Isabelle
    Spinelli, Francesca Romana
    Morello, Francesca
    Hockley, Jason
    Valesini, Guido
    Wadhwa, Meenu
    [J]. CYTOKINE, 2017, 96 : 16 - 23
  • [20] Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme
    Curtis, Jeffrey R.
    Lee, Eun Bong
    Kaplan, Irina V.
    Kwok, Kenneth
    Geier, Jamie
    Benda, Birgitta
    Soma, Koshika
    Wang, Lisy
    Riese, Richard
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 (05) : 831 - 841
12345678910